TY - JOUR
T1 - COX-2 induces T cell accumulation and IFN-γ production during the development of chromium allergy
AU - Sitalaksmi, Ratri Maya
AU - Ito, Koyu
AU - Ogasawara, Kouetsu
AU - Suto, Yoshiko
AU - Itabashi, Madoka
AU - Ueda, Kyosuke
AU - Hirasawa, Noriyasu
AU - Narushima, Takayuki
AU - Hendrijantini, Nike
AU - Kresnoadi, Utari
AU - Sasaki, Keiichi
N1 - Funding Information:
This work was supported by JSPS KAKENHI [grant No. 15K19075 (K. I.)]. We thank Dr Risako Suzuki, Toru Kawakami, Mariko Kajino, Yunosuke Yasuda, Naohiro Sekikawa, Sayaka Ono, Saki Okabe, Hiroki Ogura, Noriko Umehara, Haruka Sasaki, Tomomi Seki, Tatsuya Watanabe, Hironobu Ito, Shigehito Higuchi, Naoki Sato and Naohiko Iguchi for helpful suggestions and technical assistance.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/8/18
Y1 - 2019/8/18
N2 - Chromium (Cr) is commonly added into various metal alloys to improve some mechanical properties such as corrosion resistance, strength, and workability. However, Cr is also known to be a metal allergen for some individuals. Metal allergy is a T cell-mediated disease with symptoms of inflammation and swelling that involve inflammatory cytokines and prostaglandins. Hence, suppressing these inflammation paths by using COX-2 inhibitor might be useful in treating Cr allergy. In this study, mice were used with Cr-induced allergy challenge model. The mice were injected with celecoxib once per day for 7 days one hour after the challenge. Footpad samples were stained with haematoxylin and eosin (H&E), and lymphocytes were isolated from popliteal lymph nodes for the flow cytometric analysis. The results show that both prostaglandin E2 (PGE2), a known mediator of inflammation, and cyclooxygenases (COX)-2 have important roles in the development of Cr allergy. Further, COX-2 inhibitor, celecoxib, was effective in relieving swelling and inflammation in Cr-allergic mice concordant with suppression of IFN-γ production by CD8+ T cells and T cell accumulation in the lymph nodes. Therefore, the inhibition of COX-2 may be a therapeutic target for Cr allergy, and additional molecules in the PGE2 signalling pathway may also be an effective therapeutic target for the treatment of metal allergy.
AB - Chromium (Cr) is commonly added into various metal alloys to improve some mechanical properties such as corrosion resistance, strength, and workability. However, Cr is also known to be a metal allergen for some individuals. Metal allergy is a T cell-mediated disease with symptoms of inflammation and swelling that involve inflammatory cytokines and prostaglandins. Hence, suppressing these inflammation paths by using COX-2 inhibitor might be useful in treating Cr allergy. In this study, mice were used with Cr-induced allergy challenge model. The mice were injected with celecoxib once per day for 7 days one hour after the challenge. Footpad samples were stained with haematoxylin and eosin (H&E), and lymphocytes were isolated from popliteal lymph nodes for the flow cytometric analysis. The results show that both prostaglandin E2 (PGE2), a known mediator of inflammation, and cyclooxygenases (COX)-2 have important roles in the development of Cr allergy. Further, COX-2 inhibitor, celecoxib, was effective in relieving swelling and inflammation in Cr-allergic mice concordant with suppression of IFN-γ production by CD8+ T cells and T cell accumulation in the lymph nodes. Therefore, the inhibition of COX-2 may be a therapeutic target for Cr allergy, and additional molecules in the PGE2 signalling pathway may also be an effective therapeutic target for the treatment of metal allergy.
KW - COX-2
KW - Metal allergy
KW - celecoxib
KW - chromium
KW - inflammation
UR - http://www.scopus.com/inward/record.url?scp=85074262704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074262704&partnerID=8YFLogxK
U2 - 10.1080/08916934.2019.1662404
DO - 10.1080/08916934.2019.1662404
M3 - Article
C2 - 31587584
AN - SCOPUS:85074262704
VL - 52
SP - 228
EP - 234
JO - Autoimmunity
JF - Autoimmunity
SN - 0891-6934
IS - 5-6
ER -